About ACESO LIFE SCI Company

The Group first publicly issued shares on May 24, 2006, and was traded on the main board of Hong Kong Stock Exchange Limited on June 6, 2006 (stock code: 474.HK). The Group is a comprehensive investment group. On the basis of diversified investment, the Group will focus on developing the life science and technology industry in the future, laying out key areas and technologies for the future development of human life science, investing in incubating the world's leading life science companies, and building the world's leading life science research platform. At the same time, by cooperating and incubating the obtained exclusive overseas management rights with leading pharmaceutical companies in the Greater China region, leading overseas technology has been implemented in China and Southeast Asian countries. The Group creates ideal returns for a wide range of investors through diversified and sound business models. In addition, the Group holds Haotian International Construction Investment Group Co., Ltd. (“Haotian International Construction, 134.HK”). As at 31 March 2020, the total assets of the Group exceeded HK$5 billion.